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Restenosis after carotid angioplasty, stenting, or endarterectomy in the
Carotid and Vertebral Artery Transluminal Angioplasty Study
(CAVATAS)
McCabe DJ, Pereira AC, Clifton A, et al. Stroke 2005;36:281-6.
Conclusion: The rate of restenosis at 1 year is significantly higher in
patients whose carotid artery stenosis was treated with endovascular tech-
niques versus carotid endarterectomy. Most of the endovascular treated
patients in this study were treated with angioplasty without stenting. The
study therefore has little relevance to the current standard for endovascular
treatment of carotid artery stenosis.
Summary: The Carotid and Vertebral Artery Transluminal Angio-
plasty Study (CAVATAS) was the first multicenter randomized trial to
evaluate endovascular or surgical treatment for symptomatic extracranial
cerebrovascular disease. Patient recruitment began in 1992 and was com-
pleted in 1997. Patients were randomized to treatment of carotid artery
stenosis with either endovascular techniques or carotid endarterectomy. The
risk of stroke or death 30 days was high in both the endovascular treated
group (10%) and the endarterectomy group (9.9%). Endovascular patients
were treated with balloon angioplasty alone in 78%. Angioplasty plus stent-
ing was used in 22%. In 63% of endarterectomy patients, the endarterectomy
site was closed with a patch. The authors used standard ultrasound criteria at
the examination closest to 1 month (n 283) and 1 year (n 347) to assess
restenosis after treatment. Recurrent cerebrovascular symptoms were also
noted.
The incidence of70% stenosis in the ipsilateral carotid artery 1 year after
endovascular treatment was 18.5%, whereas it was 5.2% (P  .0001) after
carotid endarterectomy. After endovascular treatment, severe residual stenosis
was present at 1 month in 6.5% of patients. Late restenosis 70% between 1
month and 1 year occurred in 10.5% of the endovascular patients. After
endarterectomy, there was severe stenosis at 1 month in 1.7% of patients and a
total of 2.5% developed severe restenosis.In the endovascular-treated patients,
results with stenting comparedwith angioplasty alonewere better at 1month (p
 0.001) but not at 1 year. There were nine patients in the endarterectomy
group with 70% stenosis at 1 year, and none had recurrent symptoms.
Recurrent ipsilateral symptoms were more common in endovascular patients,
with severe stenosis in 5 (15.6%) of 32 compared with lessor degrees of stenosis
at 1 year in 11 (7.8%) of 141 (P  0.02). Most symptoms were transient
ischemic attacks, and there were no fatal or disabling strokes.
Comment:This paper should have been dead on arrival to the editorial
office of Stroke. It has so little relevance tomodern practice one wonders why
it was published. Problems with the CAVATAS study began with the poor
initial clinical results with both endovascular and surgical treatment. Stents
were used in only a small minority of patients in this study, which makes the
endovascular results irrelevant to modern practice. The duplex criteria for
identification of high-grade stenosis used in this study are highly sensitive
but likely have poor specificity. This may be especially so in the patients
treated with stents. We need to hope the Carotid Revascularization Endar-
terectomy Versus Stenting Trial (CREST) investigators do a better job. The
CAVATAS study does not help clarify the role of endovascular treatment in
the management of carotid artery stenosis.
The risk and benefit of endarterectomy in women with symptomatic
internal carotid artery disease
Alamowitch S, Eliasziw M, Barnett HJ, et al. Stroke 2005;36:27-31.
Conclusion: Carotid endarterectomy is not beneficial in women with
50% to 60% internal carotid artery (ICA) stenosis without other risk factors
for stroke. Men and women have similar long-term benefit from carotid
endarterectomy for 70% symptomatic lesions. Perioperative risks are
higher for women than men.
Summary:The authors used data from the North American Symptom-
atic Carotid Endarterectomy Trial (NASCET) and the Aspirin and Carotid
Endarterectomy Trial (ACE) trial. The ACE trial sought optimum aspirin
dosage to reduce risk of stroke and death in patients with carotid endarter-
ectomy. The trial was performed concurrent with NASCET, and 85% of the
centers also participated inNASCET. ACE did not require angiography, and
patients with previous endarterectomy could be included. The authors’
analysis of the ACE patients therefore focused on the 1,148 symptomatic
patients from ACE who had angiography and no previous carotid endarter-
ectomy. Also analyzed and combined with these ACE patients were 1,415
NASCET patients in the surgical arm.
Women had a higher 30-day perioperative risk of death than men
(2.3% vs 0.8%, P  .002). There were no statistical differences in
perioperative stroke and death (7.6% vs 5.9%). The absolute risk reduc-
tion at 5 years in stroke from carotid endarterectomy was similar in men
(17.3%) and women (15.1%) with 70% ICA stenosis. With 50% to 69%
ICA stenosis, the absolute risk reduction in men was 10% (P  .02),
whereas there was no benefit in women (absolute risk reduction, 3%; P 
.94). The authors used a stroke prognosis score to assign risk to medically
treated women: 3 points for hemispheric transient ischemic attack,
previous stroke, or history of diabetes mellitus; 2 points for age 70
years, stroke; 1 point for severe hypertension or history of myocardial
infarction. Carotid endarterectomy benefited only 29% of women with
50% to 69% ICA stenosis who had the highest total score of 8 to 15, with
an absolute risk reduction of 8.9%.
Comment: This study represents a post hoc subgroup analysis that
combines data from two large studies of similar design but different prede-
termined goals. Nevertheless, the suggestion that women do more poorly
than men with carotid endarterectomy, even for high-grade stenosis, is
consistent with the analysis from the European Carotid Surgery Trial as well
as NASCET. The overall suggestion of higher risk for vascular intervention
in women with vascular disease is relatively consistent in the literature. The
reasons for this are unknown but certainly seem to constitute an area of
important future investigation.
Long-term outcome following thromboembolectomy in the upper
extremity
Licht PB, Balezantis T, Wolff B, et al. Eur J Vasc Endovasc Surg 2004;28:
508-12.
Conclusion: Perioperative mortality is high after acute embolism to
the upper extremity. Mortality after discharge from the hospital also remains
significantly higher than that of the background population.
Summary: The authors sought to evaluate short-term and long-term
mortality and morbidity in patients treated for acute upper extremity isch-
emia. This was a single-center retrospective study. During the study’s
11-year period, 148 consecutive patients were admitted to the authors’
center with acute upper extremity ischemia. Data were collected through
chart review and interviews of survivors, of which 96% participated in clinical
follow-up.
The median age of the patients was 78 years (range, 27 to 93 years);
64%were women, 36%weremen. Duration of ischemia prior to presentation
was 12 hours in 49%, between 12 to 24 hours in 25%, and 24 hours in
26%. Ischemic pain was present in 52%, paresthesias in 30%, and some degree
of paralysis in 26%. The right upper extremity was involved in 61% of the
cases. In 88%, the diagnosis of acute upper extremity arterial occlusion was
made from history and physical examination alone. In 61% of patients, a
cardiac embolus (atrial fibrillation, valvular heart disease, or ischemic heart
disease) was thought to be the reason for ischemia, and 3% appeared to have
local brachial artery thrombosis. The etiology of the embolismwas unknown
in 37%.
Balloon catheter embolectomy was all that was performed in 138
patients (93%). Five patients underwent local arterial reconstruction of the
brachial artery, and another five patients received intraoperative thrombo-
lytic therapy. Seven patients required re-embolectomy during the hospital
stay; five were successful. Two patients required amputation.
There was no statistical difference in arm function postoperatively
among the patients who presented with12 hours of ischemia versus those
who presented with 12 to 24 hours of ischemia, and those who presented
with 24 hours of ischemia. Overall, 84% manifested normal arm function
postoperatively. Slightly decreased arm function was present postoperatively
in 13%, and 3% had severely decreased postoperative arm function. Long-
term survival was not related to anticoagulation.
Comment: The article indicates embolism to the upper extremity can
be treated with a good surgical outcome with respect to the limb, but a poor
short-term and long-term outcome with respect to patient survival. The
authors confirmed a reason for a cardiac source in only 61% of their patients,
but it is very likely emboli large enough to occlude the brachial artery
virtually always originate from a cardiac chamber. Unless there is a specific
contraindication, long-term anticoagulation would seem reasonable in any
patient with an upper extremity embolus. Perhaps survival is not improved,
but repeat embolism may be avoided.
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